Uno Tsukasa, Niioka Takenori, Hayakari Makoto, Sugawara Kazunobu, Tateishi Tomonori
Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki, Japan.
Ther Drug Monit. 2007 Jun;29(3):333-9. doi: 10.1097/FTD.0b013e31805c956e.
A simple and sensitive column-switching high-performance liquid chromatographic method for the simultaneous determination of warfarin enantiomers and their metabolites, 7-hydroxywarfarin enantiomers, in human plasma is described. Warfarin enantiomers, 7-hydroxywarfarin enantiomers, and an internal standard, diclofenac sodium, were extracted from 1 mL of a plasma sample using diethyl ether-chloroform (80:20, v/v). The extract was injected onto column I (TSK precolumn BSA-C8, 5 microm, 10 mm x 4.6 mm inside diameter) for cleanup and column II (Chiralcel OD-RH analytical column, 150 mm x 4.6 mm inside diameter) coupled with a guard column (Chiralcel OD-RH guard column, 10 mm x4.6 mm inside diameter) for separation. The mobile phase consisted of phosphate buffer-acetonitrile (84:16 v/v, pH 2.0) for clean-up and phosphate buffer-acetonitrile (45:55 v/v, pH 2.0) for separation. The peaks were monitored with an ultraviolet detector set at a wavelength of 312 nm, and total time for chromatographic separation was approximately 25 minutes. The validated concentration ranges of this method were 3 to 1000 ng/mL for (R)- and (S)-warfarin and 3 to 200 ng/mL for (R)- and (S)-7-hydroxywarfarin. Intra- and interday coefficients of variation were less than 4.4% and 4.9% for (R)-warfarin and 4.8% and 4.0% for (S)-warfarin, and 5.1% and 4.2% for (R)-7-hydroxywarfarin and 5.8% and 5.0% for (S)-7-hydroxywarfarin at the different concentrations. The limit of quantification was 3 ng/mL for both warfarin and 7-hydroxywarfarin enantiomers. This method was suitable for therapeutic drug monitoring of warfarin enantiomers and was applied in a pharmacokinetic study requiring the simultaneous determination of warfarin enantiomers and its metabolite, 7-hydroxywarfarin enantiomers, in human volunteers.
本文描述了一种简单灵敏的柱切换高效液相色谱法,用于同时测定人血浆中华法林对映体及其代谢物7-羟基华法林对映体。使用乙醚 - 氯仿(80:20,v/v)从1 mL血浆样品中提取华法林对映体、7-羟基华法林对映体和内标双氯芬酸钠。提取物注入柱I(TSK预柱BSA - C8,5μm,10 mm×4.6 mm内径)进行净化,然后注入柱II(Chiralcel OD - RH分析柱,150 mm×4.6 mm内径)并与保护柱(Chiralcel OD - RH保护柱,10 mm×4.6 mm内径)联用进行分离。净化用流动相为磷酸盐缓冲液 - 乙腈(84:16 v/v,pH 2.0),分离用流动相为磷酸盐缓冲液 - 乙腈(45:55 v/v,pH 2.0)。用设定波长为312 nm的紫外检测器监测峰,色谱分离总时间约为25分钟。该方法验证的浓度范围为(R)-和(S)-华法林为3至1000 ng/mL,(R)-和(S)-7-羟基华法林为3至200 ng/mL。不同浓度下,(R)-华法林的日内和日间变异系数分别小于4.4%和4.9%,(S)-华法林分别为4.8%和4.0%,(R)-7-羟基华法林分别为5.1%和4.2%,(S)-7-羟基华法林分别为5.8%和5.0%。华法林和7-羟基华法林对映体的定量限均为3 ng/mL。该方法适用于华法林对映体的治疗药物监测,并应用于一项要求同时测定人志愿者中华法林对映体及其代谢物7-羟基华法林对映体的药代动力学研究。